# Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus

> **NCT00556192** · PHASE2 · COMPLETED · sponsor: **Chinese University of Hong Kong** · enrollment: 20 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** rituximab

## Key facts

- **NCT ID:** NCT00556192
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2012-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00556192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00556192, "Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00556192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*